Should I buy or sell Xilio Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares. View XLO analyst ratings or view top-rated stocks .

How have XLO shares performed in 2024?

Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO shares have increased by 109.1% and is now trading at $1.15. View the best growth stocks for 2024 here .

When is Xilio Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our XLO earnings forecast .

How were Xilio Therapeutics' earnings last quarter?

Xilio Therapeutics, Inc. (NASDAQ:XLO) posted its quarterly earnings data on Wednesday, December, 1st. The company reported ($21.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $19.67.

When did Xilio Therapeutics IPO?

Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

How do I buy shares of Xilio Therapeutics?

Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:XLO

Xilio Therapeutics (XLO) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)

Free XLO Stock Alerts

$1.15

-0.13 (-10.16%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.12
▼
$1.28
50-Day Range: $0.55
▼
$1.53
52-Week Range: $0.49
▼
$3.40

Volume: 338,694 shs
Average Volume: 1.07 million shs
Market Capitalization: $39.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Xilio Therapeutics alerts:

Xilio Therapeutics MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$368,790 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.53) to ($1.18) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.68 out of 5 stars

Medical Sector

429th out of 911 stocks

Pharmaceutical Preparations Industry

189th out of 411 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Xilio Therapeutics.

5.0

Short Interest

Percentage of Shares Shorted
0.67% of the float of Xilio Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Xilio Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Xilio Therapeutics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Xilio Therapeutics does not currently pay a dividend.
Dividend Growth
Xilio Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XLO.

4.0

News and Social Media Coverage

News Sentiment
Xilio Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Xilio Therapeutics this week, compared to 0 articles on an average week.
Search Interest
16 people have searched for XLO on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.
MarketBeat Follows
5 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xilio Therapeutics insiders have bought 78,533.26% more of their company's stock than they have sold. Specifically, they have bought $368,790.00 in company stock and sold $469.00 in company stock.
Percentage Held by Insiders
Only 4.60% of the stock of Xilio Therapeutics is held by insiders.
Percentage Held by Institutions
54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.53) to ($1.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xilio Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xilio Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xilio Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Xilio Therapeutics Stock (NASDAQ:XLO)

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

XLO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XLO Stock News Headlines

April 4, 2024 | insidertrades.com

Gilead Sciences, Inc. Buys 485,250 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

April 17, 2024 | msn.com

Xilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

April 12, 2024 | stocknews.com

3 Biotech Stocks to Invest In Right Now for Long-Term Gains

April 2, 2024 | investorplace.com

XLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023

April 1, 2024 | globenewswire.com

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

March 29, 2024 | marketwatch.com

Xilio Shares Take Flight Premarket After Gilead Deal

March 28, 2024 | investorplace.com

Why Is Xilio Therapeutics (XLO) Stock up 168% Today?

April 19, 2024 | American Alternative (Ad)

Your Money is Not Safe

March 28, 2024 | marketwatch.com

Xilio Therapeutics Plans Private Placement, Job Cuts

March 28, 2024 | markets.businessinsider.com

Xilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of Jobs

March 28, 2024 | globenewswire.com

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

February 28, 2024 | globenewswire.com

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

February 27, 2024 | morningstar.com

Xilio Therapeutics Inc XLO

January 31, 2024 | finance.yahoo.com

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

January 8, 2024 | finance.yahoo.com

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

December 28, 2023 | seekingalpha.com

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

December 7, 2023 | finance.yahoo.com

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

November 10, 2023 | msn.com

Xilio Therapeutics GAAP EPS of -$0.61

November 9, 2023 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

November 8, 2023 | markets.businessinsider.com

Promising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio Therapeutics

November 3, 2023 | finance.yahoo.com

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

October 31, 2023 | finance.yahoo.com

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

September 27, 2023 | finance.yahoo.com

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 5, 2023 | markets.businessinsider.com

Xilio Therapeutics Appoints Katarina Luptakova As CMO

September 5, 2023 | finance.yahoo.com

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer

September 5, 2023 | finance.yahoo.com

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

See More Headlines

Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/01/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:XLO
CUSIP: N/A
CIK: 1840233
Web: www.xiliotx.com
Phone: 857-524-2466
Fax: N/A
Employees: 81
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,400,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -126.55%
Return on Assets: -89.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.02
Quick Ratio: 3.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.34 per share
Price / Book: 0.86

Miscellaneous

Outstanding Shares: 34,470,000
Free Float: 32,887,000
Market Cap: $39.64 million
Optionable: Not Optionable
Beta: -0.12

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Rene Russo BCPS (Age 49)
Pharm.D., President, CEO & Director
Comp: $888.49k
Mr. Kevin M. Brennan (Age 54)
Senior VP of Finance & Accounting
Mr. Christopher Frankenfield
Chief Operating Officer
Dr. Uli Bialucha Ph.D.
Chief Scientific Officer
Julissa Viana
Vice President of Corporate Communications
Ms. Stacey J. Davis
Chief Business Officer
Dr. Katarina Luptakova M.D.
Chief Medical Officer
Dr. Scott Coleman Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XLO Stock Analysis - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares.
View XLO analyst ratings or view top-rated stocks.
How have XLO shares performed in 2024?: Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO shares have increased by 109.1% and is now trading at $1.15.
View the best growth stocks for 2024 here.
When is Xilio Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XLO earnings forecast.
How were Xilio Therapeutics' earnings last quarter?: Xilio Therapeutics, Inc. (NASDAQ:XLO) posted its quarterly earnings data on Wednesday, December, 1st. The company reported ($21.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by $19.67.

When did Xilio Therapeutics IPO?: Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.
How do I buy shares of Xilio Therapeutics?: Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XLO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial